Alternatives to testosterone replacement: testosterone restoration

Andrew McCullough

The European Male Aging Study has demonstrated that the hypogonadism of male aging is predominantly secondary. Theoretically with appropriate stimulation from the pituitary, the aging testis should be able to produce eugonadal levels of testosterone. The strategies for the treatment of late onset hypogonadism (LOH) have focused on replacement with exogenous testosterone versus restoration of endogenous production. The purpose of this article is to review existing peer-reviewed literature supporting the concept of restoration of endogenous testosterone in the treatment of LOH.

Asian Journal of Andrology (2015) 17, 201–205; doi: 10.4103/1008-682X.143736; published online: 19 December 2014

Keywords: aromatase inhibitor; clomiphene citrate; enclomiphene; secondary hypogonadism

INTRODUCTION

The decrease of testosterone (T) levels with aging has been long since observed. Longitudinal studies have clearly documented the decline in T with aging. Consequences of low T levels in the human male and the benefit of the normalization of T levels value have been well established. The etiology of late onset hypogonadism (LOH) has been attributed to a decrease in the secretion of hypothalamic and pituitary gonadotropins and a decrease in Leydig cell numbers and responsiveness in the aging male. Yet, the European Male Aging Study (EMAS) has characterized 85% of hypogonadal men as secondary that is, the testes are being insufficiently stimulated by the hypothalamic-pituitary axis.

The risk benefits ratio of testosterone replacement (TREP) therapies has recently been questioned. Three widely publicized studies (two large retrospective studies and one small prospective) have brought into doubt the cardiovascular safety of TREP despite prior studies suggesting that TREP might be beneficial to the cardiovascular system. In the words of the recently convened Food and Drug Administration (FDA) advisory panel “these studies do not provide conclusive evidence of increased cardiovascular risk associated with the use of testosterone therapy.” The European Pharmacovigilance Risk Assessment Committee also did not find that current evidence supported the purported association between TREP and an increased cardiovascular risk.

For decades, the only FDA approved treatment for hypogonadism has been TREP. Current guidelines for approvals are all based on T restoration (TRES) to normalize T levels and not symptomatic improvement. Barring major lifestyle changes, men diagnosed with hypogonadism will require treatment for life, not unlike another highly prevalent condition, type 2 diabetes. Yet, the treatment of type 2 diabetes is not universally insulin replacement, but either oral medication to increase insulin sensitivity or insulin secretion. Fifty-eight percent of diabetics are on oral hypoglycemics with only 12% of diabetics on replacement therapy with insulin. Why is the only recommended therapy for hypogonadism replacement, particularly since 85% of men are secondarily hypogonadal? These are not men with absent gonadotropins, but men with inappropriately low gonadotropins for the low levels of T. Is there another possible therapeutic strategy other than replacement? Can we “restore” T production in the aging male by stimulation of the testes? Current exogenous therapies are fraught with the potential of abuse, possible testosterone transfer to other parties, erythrocytosis, induction of infertility by pituitary suppression, gynecomastia from hyper-estrogenism, the morbidity of a lifetime of intramuscular injections or testosterone pellet insertions and the expense of proprietary applications. The purpose of this article is to explore the current status of TRES therapies. The reader should be warned that none of the discussed therapies is FDA approved.

HUMAN CHORIONIC GONADOTROPINS

Human chorionic gonadotropin (HCG) is purified from the urine of pregnant women or through recombinant technology. HCG was discovered 80 years ago and has been commercially available since 1932. It has been used in women to promote the final stages of follicular maturation and progression of the immature oocyte in assisted reproductive strategies. In a retrospective uncontrolled trial of 13 young infertile men with profound hypogonadotropic hypogonadism, HCG was used to induce and maintain spermatogenesis by increasing intra-testicular testosterone production. After induction of spermatogenesis with HCG and human menopausal gonadotropin (HMG), in the third phase of the study, men were treated with maintenance HCG instead of TREP. Though T levels were maintained, prolonged treatment with HCG alone resulted in a decrease in sperm concentrations and testicular volumes over the HCG/HMG phase. Estradiol levels were not reported in the study. Jawor et al. demonstrated the benefit of combined use of low-dose HCG in 29 young men (250–500 IU every other day for 3 weeks).
with normal reproductive physiology treated simultaneously with exogenous IM T (200 mg weekly) and escalating doses of HCG (0, 125, 250 and 500 IU). Whereas intra-testicular T was suppressed to 5% of the baseline value on T alone, with concomitant administration of 250 IU of HCG intra-testicular T levels were maintained at baseline throughout the study. In a retrospective review of 4 years of hypogonadal men presenting to the Baylor andrology clinic, Hsieh et al. reported on 26 men, concerned about their fertility, who were treated simultaneously with HCG treatment and exogenous T (19 IM T 200 mg week^{-1} and 7 with transdermal gel) for an average of 6.2 months. Despite a mean posttreatment level T level of 1055 ng dl^{-1} for the study population. Serum gonadotropins were not reported. The Baylor study demonstrated the ability of low-dose HCG to maintain spermatogenesis despite the administration of exogenous T. HCG has been used to rescue spermatogenesis in previous anabolic steroid abusers. Turek et al. reported the successful treatment of an azoospermic anabolic steroid abuser with HCG.

Late onset hypogonadism is probably secondary to senescence of central and peripheral endocrine axis. Nonetheless Kaufman et al. demonstrated comparable pituitary luteinizing hormone (LH) surges to LH releasing hormone (LHRH) stimulation in 10 elderly monks (mean age 72) and 10 young men (mean age 33). He proposed that the aging pituitary is able to respond to gonadotropins despite decreased baseline GnRH pulses from the hypothalamus. Liu et al. demonstrated that LOH could be treated with HCG. He conducted a 3-month randomized double-blind placebo controlled trial of bi-weekly 5000 IU units of HCG in 40 men with a primary endpoint of a 20% increase in muscle strength. The average age was 67 and baseline T was 320 ng dl^{-1}. All men were “healthy, ambulatory, and community-dwelling.” The only entry criterion was a T level < 420 ng dl^{-1}. Labs were checked monthly and at 1 month after termination. Ultrasonographic determined testicular volume was assessed before, at the end of study and 1 month later. Even though a significant improvement in muscle strength was not demonstrated, a tremendous amount of valuable information was obtained. Lean body mass was improved. T and E-2 levels increased 145% (778 ng dl^{-1}) and 157% (89 pg ml^{-1}) respectively while gonadotropins plummeted and testicular volumes decreased significantly. Two men had T levels above 1000 ng dl^{-1} and three men developed nipple tenderness. Despite the effectiveness of HCG in the normalization of serum T in older men, the decrease in testicular volume, suppression of gonadotropins and a uniform supraphysiological increase in E-2 gives pause for concern for long-term use as monotherapy in LOH. Larger long term safety and efficacy trials are needed. As most of testicular volume is comprised of seminiferous tubules, the finding of testicular size reduction is in stark contrast to the low dose HCG/IM T Hsieh et al. study which revealed preservation of fertility. Seminal parameters were not reported by Liu et al. and testicular volumes were not reported by Hsieh et al.

**CLOMIPHENE CITRATE**

Like HCG, clomiphene citrate (CC) was originally designed for female infertility. Approved by the FDA in 1967 it has since become an inexpensive generic drug. It is a selective estrogen receptor modulator (SERM) comprised of a 38%/62% racemic mixture of cis and trans isomers, zuclophene and enclomiphene, respectively. It has antagonistic effects on the estrogen receptors in the hypothalamus and the pituitary thereby increasing endogenous gonadotropin-releasing hormones (GnRH), LH and follicle-stimulating hormone (FSH). It ability to increase LH in men was recognized as early at 1968. As with all SERMs organ estrogen agonistic effects are also possible. In a study aimed at using CC challenges to diagnose hypogonadotropic hypogonadism, Paulsen demonstrated significant increases in LH, FSH and T in normal older men taking 50 mgs of CC twice a day. Winters et al. showed the CC was able to block the LH and FSH suppression that occurs with exogenous T and estrogen administration, thus demonstrating that estrogen was the primary inhibitory hormone on GnRH, LH and FSH. Over the ensuing decades, CC was used to increase male fertility with mixed results. Though an increase in T and estrogen level was consistently demonstrated, no consistent effect of seminal parameters or pregnancy rates was observed. A 6 months multicenter international placebo-controlled study cast doubts on the efficacy of CC on idiopathic male infertility. It is important to realize that in the international study, the infertile population was eugonal with the mean baseline T levels of 481 ng dl^{-1}. Well-controlled studies in the hypogonadal infertile male are lacking, despite the high prevalence of secondary hypogonadism in this group of men.

Tenover and Bremner looked at an 8 weeks trial of CC (50 mg BID) in 5 healthy older and 5 eugonadal men (mean age 73 vs 29 years; mean baseline T 518 vs 498) and demonstrated that older men both increased LH and FSH and T and E-2. Though levels of T were significantly lower in the older group, the levels achieved in both groups were at least comparable to those achieved with many current day exogenous treatments. Lim observed normalization of testosterone levels in 5 hypogonadal uremic men with uniform increase in libido, sexual potency, and a general sense of well-being using 100 mgs of CC daily for as long as 12 months. The normalization of T continued for 4–5 months after discontinuation of therapy. Plasma estradiol levels were elevated at baseline and did not change significantly from baseline.

Guay et al. challenged 21 older men with erectile dysfunction (ED) and secondary hypogonadism with 50 mg CC bid for 7 days and normalized their T, demonstrating that at that least in the short term, the concept of TRES was possible in older men. He then expanded the concept with an 8 weeks double blind placebo controlled crossover study in older men (mean age 62) with secondary hypogonadism and ED (documented with nocturnal penile tumescence scan [NPT]). Again, normalization of serum testosterone was seen but no improvement was seen in NPT or sexual function questionnaires in the group as a whole. When the study population was split between younger and older groups (mean age 53 and 66 respectively) in a post hoc analysis, not surprisingly, the differences between the treatment groups with the sexual function questionnaires and NPT testing achieved statistical significance. The older men were more likely to have “end organ” disease refractory to hormonal manipulation. This was the first demonstration that CC could not only normalize T levels in SHGD but result in symptomatic improvement. Guay et al. then began treating men in his practice with SHGD with CC (50 mg) 3 times a week. He reported an observational series of 173 men with ED and SHGD treated for 4 months. The diagnosis of ED was based on self-report and not a validated questionnaire, and a placebo arm was lacking. The outcome was measured as “responder” to treatment (successful intercourse > 75% of the time), partial responder (successful intercourse 50%–75% of the time) and nonresponder. As in his previous studies, LH, FSH and free testosterone levels increased. Sexual function improved in 75% and did not change in 25%. Age and vascular co-morbidities negatively affected the response rates.

Taylor and Levine in an observational study compared the biochemical efficacy of CC to exogenous gel treatment (testosterone...
replacement therapy (TRT) in 104 men (65 CC vs 39 on TRT). The groups were not strictly identical but demonstrated comparable increases in testosterone with an 182 $ monthly savings in the CC group. Prostate-specific antigen (PSA) levels and hematocrit (HCT) did not significantly change in follow-up (23 months) 37 Moskovic et al. demonstrated an excellent chemical response in a younger cohort of 29 men (mean age 44) followed for 3 years on CC 25 mgs every other day. In addition, despite an unusually high percentage of men with altered bone mineral density (BMD) at baseline (75%) BMD normalized at 1 year in 25%. No improvement in BMD was observed after the first year. Though estradiol increased, significantly no gynecomastia or breast tendereness occurred. No side-effects were reported. 38

The efficacy of CC in relieving the symptoms of hypogonadism is often anecdotally reported as being inferior to exogenous therapy without the support of randomized double-blind studies. Katz et al. retrospectively looked at symptom relief with CC (25 mg every other day) in 86 young (mean age 29) hypogonadal men, most of whom were presenting for infertility (57%) over a 4 years period at a Sloan Kettering andrology practice. The men were followed for a mean of 19 months. Surprisingly, the median number of positive baseline responses on the androgen deficiency in aging males (ADAM) questionnaire was 5 that dropped to 2. These "generally very healthy" young men started at a mean T level of 192 ng dl⁻¹ and increased their T to 485 (despite a target treatment level of 550 ng dl⁻¹). The symptoms that showed significant increases included "decreased libido, lack of energy, decreased life enjoyment, sad/grumpy, decreased sports performance." 39 The lack of a placebo arm weakens the strength of the study. Further support of the efficacity of CC in relieving hypogonadal symptoms comes from a retrospectively gathered observational comparative study from Baylor by Ramasamy et al. In examining the effect of CC versus replacement therapy on hypogonadal symptoms, no significant differences were seen in between T injections, T gels or CC. T levels were highest with injections (1104 ng dl⁻¹) versus CC (504 ng dl⁻¹) or the gels (412 ng dl⁻¹). 40 The lack of a difference in symptom relief supports the concept that symptom relief may be tied to a threshold level that is achieved with TRES and TREP. Unfortunately, pretreatment quantitative ADAM scores (QADAM) were not reported, and the QADAM has not been fully psychometrically validated.

Recently, there has been interest in the trans isomer of CC (EC). Distinct differential pharmacokinetics of the two isomers have been demonstrated. 41 Though the Cₘₙₗ and Tₘₙₗ were comparable, the area under the curve for the isomers was dramatically different after a single dose administration of 50 mgs of CC in women with polycystic ovaries. At 456 h, ZC was detected in 9/9 patients versus 1/9 for EC. 42 The half-life of EC is 7–8 h. 43 EC was evaluated in an early proof of concept randomized, open-label, fixed dose, active-control (7 EC and 5 exogenous gel), two-center phase IIB study in 12 men with secondary hypogonadism treated previously with topical testosterone. After T discontinuation of exogenous T, T levels in both groups averaged 165 ng dl⁻¹. After treatment T levels increased in both groups to over 540 ng dl⁻¹ but decreased to baseline after cessation of treatment suggesting that the hypothalamic testicular axis reverts to its pretreatment state and continued therapy is necessitated. Whereas, sperm counts were increased in all men on EC at 6 months only 2 of 5 of gel patients increased their sperm concentrations to over 20 million ml⁻¹. Guanosine triphosphate (GTP) increased only in the EC arm. 44 In follow-up clinical trials, safety and clinical efficacy were comparable to a gel preparation while preserving sperm counts. Sperm counts were decreased in the men treated with gels. Side-effects were comparable to CC. The most significant adverse events were hot flushes (10%), visual disturbances headaches, nausea and vomiting. Aside from the hot flushes, all events occurred in < 5% of the study population. 45 The ease of use, low side-effect profile, therapeutic efficacy and preservation of fertility, make EC if approved an attractive therapeutic alternative to standard TREP.

AROMATASE INHIBITORS

Aromatase is a cytochrome P450 enzyme responsible for the biosynthesis of estrogen from testosterone. Its evolutionary importance in bone metabolism is underscored by its ubiquitous presence in the vertebrate phyla and absence in the nonvertebrate phyla. 46 The importance of estrogen in men is demonstrated in men with congenital aromatase deficiency. Male aromatase deficiency syndrome caused by a mutation in the CYP19 is characterized by elevated testosterone, LH, FSH, absent estradiol levels, osteopenia, failure of epiphyseal plate closure and tall stature. 47 Aromatase has been found in the brain, testes, adipose tissue, muscle, hair, bone and vascular tissue. 48 Aromatase inhibitors (AIs) are classified as steroid or nonsteroidal. First generation AIs such as aminoglutethimide are nonspecific and cause suppression of the production of adrenal steroids, necessitating adrenal steroid replacement. The third generation nonsteroidal AIs such as anastrozole and letrozole are highly specific and potent for aromatase and are well-tolerated. Adrenal steroid replacement is not necessary. Nonsteroidal third generation AIs have been used to lower estrogens in women with metastatic breast cancer since the early 2000’s. Much is known about the pharmacokinetics and safety of the AIs in women. The recommended dose is 1 mg a day. Estradiol levels are suppressed to 0.8 pg ml⁻¹, with 70% of suppression achieved in 24 h and 80% by 14 days. Estrogen synthesis suppression is maintained for up to 6 days after discontinuation of therapy. The drug is rapidly absorbed with a bioavailability of 85% and a peak serum level achieved at 2 h from ingestion in the fasting state. The pharmacokinetics are linear over a dose of 1 mg to 20 mg. Steady state levels are 3–4 times that of a single dose and are reached at 7 days. Hepatic metabolism and renal excretion are 85% and 10% respectively. No age-related effects were seen, no dose adjustment was needed in renal impairment or mild hepatic cirrhosis. 49 A pharmacokinetics study of a 1 mg of anastrozole in 20 healthy male volunteers revealed a 100% bioavailability, Tₘ₉₉ at 1.2 h, a Tₘ₉₉ of 42 h and a Cₘ₉₉ of 1000 ng ml⁻¹. 50 In women the most common side effects in these women with metastatic breast cancer (>10%) were hot flashes, nausea, asthenia, pain, headache, back pain, bon pain, increased cough, dyspnea, pharangitis, and peripheral edema. 49

Though safe and effective in this very ill female population it has been associated with 11% incidence of osteoporosis also seen in congenital male aromatase deficiency syndrome and estrogen receptor deficiency. 47, 51 Fears about bone demineralization with AI’s have limited their long term use in men. Are these fears justified? In a 1 year randomized placebo-controlled trial of anastrozole in 69 hypogonadal men there were no statistically significant changes in BMDs from baseline in the treatment group. The posterior-anterior spine BMD decreases seen (1.7%), only achieved statistically significance because the placebo group increased (0.7%). The standard deviation on baseline determinations of posterior-anterior spine BMD was 17% making the solitary observation of a 1.7% decrease in BMD of questionable clinical significance. Trabecular BMD assessed by quantitative computerized tomography and multiple measured highly sensitive bone turnover markers (BTM) demonstrated no significant differences from the placebo group. 52 In another placebo-controlled study of 42 obese hypogonadal men followed for 6 months using another AI, letrozole, no significant differences in BMD or BTM were seen. Finally, in the
5 years comparator trial of anastrozole and tamoxifen in 189 women with breast cancer, most of the significant bone loss occurred within the first 2 years. The authors state "no woman with a normal BMD at baseline became osteoporotic at 5 years and only those women with a T-score of <−1.5 are at risk of developing osteoporosis." In fact, there have never been any studies published in men that demonstrate a loss of BMD with AI use in men.

How is that possible? Unlike the male deficiency syndrome, estradiol is not eliminated with AIs but is reduced. Published male trials reveal a 50%–65% reduction in serum estradiol levels in men on AIs to a level of 17–34 pmol L−1,14,23,45 Testosterone levels in hypogonadal men are increased by as much as 144%,5,25 Approximately, 20% daily estradiol is produced in the testes, accounting for 60% the circulating estradiol.56,57 At steady state serum levels, the serum molar concentration of aromatase is 4–10 times that of serum testosterone levels in a hypogonadal man effectively blocking aromatase conversion peripherally. Nonetheless in the testes where the testosterone concentrations reach levels up to 200 times the serum,58 the AIs will stochiometrically never successfully compete with endogenous testosterone and estrogen will always be produced. With significantly increased testosterone levels and modest decreases in circulating estrogen levels, it is not surprising that the markers of BTMs have not shown any changes in placebo-controlled trials.

In an early placebo-controlled study of the steroidal AI, testolactone, in eugonadal men with idiopathic infertility, testosterone was found to increase modestly with a no change in seminal parameters or estradiol levels.59 Pavlovich looking at testolactone in hypogonadal infertile men demonstrated a 30% increase in testosterone, a decrease in estradiol levels and an improvement in seminal parameters. As with the SERMs the data on the use of AIs to improve male fertility is equivocal. What is not arguable is the effect of the nonsteroidal AIs with the SERM's the data on the use of AIs to improve male fertility are minimal. HCTs, liver functions and urinary symptoms were comparable or better than those found in comparable topical testosterone studies

Alternatives to Testosterone replacement
A McCullough

establish a long-term efficacy and safety restorative therapies. Early clinical trials of the compound enclomiphene are encouraging and hopefully will lead to a change in paradigm from TREP to TRES.

COMPETING INTERESTS
The authors declare that they have no competing interests.

REFERENCES
1. Mohr BA, Bhasin S, Link CL, O’Donnell AB, McKinlay JB. The effect of changes in adiposity on testosterone levels in older men: longitudinal results from the Massachusetts male aging study. J Endocrinol 2006; 155: 443–52.
2. Harman SM, Metter EJ, Tobin JD, Pearson J, Blackman MR, et al. Longitudinal effects of aging on serum total and free testosterone levels in healthy men. Baltimore Longitudinal study of aging. J Clin Endocrinol Metab 2001; 86: 724–31.
3. Matsumoto AM. Andropause: clinical implications of the decline in serum testosterone levels with aging in men. J Gerontol A Biol Sci Med Sci 2002; 57: M76–99.
4. Zirkin BR, Tenover JL. Aging and declining testosterone: past, present, and hopes for the future. J Androl 2012; 33: 1111–8.
5. Tajar A, Forti G, O’Neill TW, Lee DM, Silman AJ, et al. Characteristics of secondary, primary, and compensated hypogonadism in aging men: evidence from the European male aging study. J Clin Endocrinol Metab 2010; 95: 1810–8.
6. Xu L, Freeman G, Cowing BJ, Schooling CM. Testosterone therapy and cardiovascular events among men: a systematic review and meta-analysis of placebo-controlled randomized trials. BMC Med 2013; 11: 108.
7. Vigen R, O’Donnell CI, Barden AE, Grunwald GK, Maddox TM, et al. Association of testosterone therapy with mortality, myocardial infarction, and stroke in men with low testosterone levels. JAMA 2013; 310: 1829–36.
8. Basaria S, Coviello AD, Traversin TG, Storer TW, Farewell VR, et al. Adverse events associated with testosterone administration. N Engl J Med 2010; 363: 109–22.
9. Shores MM, Smith NL, Forsberg CW, Anawalt BD, Matsumoto AM. Testosterone treatment and mortality in men with low testosterone levels. J Clin Endocrinol Metab 2012; 97: 2050–8.
10. Muraliedharan V, Marsh H, Kapoor D, Channer KS, Jones TH. Testosterone deficiency is associated with increased risk of mortality and testosterone replacement improves survival in men with type 2 diabetes. J Endocrinol 2013; 169: 725–33.
11. Committee Tidsmark. Joint Meeting for Bone, Reproductive and Urologic Drugs Advisory Committee (Brudac) and the Drug Safety and Risk Management Advisory Committee; 2014. p. 1–209. Available from: http://www.fda.gov/downloads/AdvisoryCommittees/ CommitteesMeetingMaterials/Drugs/ReproductiveHealthDrugsAdvisoryCommittee/UCM412536.pdf. (Last accessed on 2014 Dec 15).
12. Committee PRA. PRAC Review does not Confirm Increase in Heart Problems with Testosterone Medicines, 2014. p. 1–2. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Referrals_document/Testosterone_31_Recommendation_provided_by_Pharmacovigilance_Risk_Assessment_Committee_WCS00175213.pdf. (Last accessed on 2014 Sep 3).
13. Bhasin S, Cunningham GR, Hayes FJ, Matsumoto AM, Snyder PJ, et al. Testosterone therapy in men with androgen deficiency syndromes: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 2010; 95: 2536–59.
14. Stahlman J, Britto M, Fitzpatrick S, McWhirter C, Testino SA, et al. Serum testosterone levels in non-dosed females after secondary exposure to 1.62% testosterone gel: effects of clothing barrier on testosterone absorption. Curr Med Res Opin 2012; 28: 291–301.
15. de Boer W. Hyperandrogenism after transfer of topical testosterone gel: case report and review of published and unpublished studies. Hum Reprod 2009; 24: 425–8.
16. Bachman E, Traversin TG, Basaria S, Davda MN, Guo W, et al. Testosterone induces erythrocytosis via increased erythropoietin and suppressed hepcidin: evidence for a new erythropoietin/hemoglobin set point. J Gerontol A Biol Sci Med Sci 2014; 69: 725–35.
17. If FF, di Pierro I, Brown R, Cunningham I, Hanedelman DJ, et al. Trough serum testosterone predicts the development of polycythemia in hypogonadal men treated for up to 21 years with subcutaneous testosterone pellets. Eur J Endocrinol 2010; 162: 385–90.
18. Sampleski MK, Looi Y, Wong K, Lo KC, Grober ED, et al. Testosterone use in the male infertility population: prescribing patterns and effects on semen and hormonal parameters. Fertil Steril 2014; 101: 64–9.
19. Borst SE, Mulligan T. Testosterone replacement therapy for older men. Clin Interv Aging 2007; 2: 561–6.
20. Taylor F, Levine L. Clomiphene citrate and testosterone gel replacement therapy for male hypogonadism: efficacy and treatment cost. J Sex Med 2010; 7: 269–76.
21. Practice Committee of American Society for Reproductive Medicine, Birmingham, Alabama. Gonadotropin preparations: past, present, and future perspectives. Fertil Steril 2008; 90: S13–20.
22. Depenbusch M, von Eckardstein S, Simon I, Nieschlag E. Maintenance of spermatogenesis in hypogonadotrophic hypogonadal men with human chorionic gonadotropin alone. Eur J Endocrinol 2002; 147: 617–20.
23. Coviello AD, Matsumoto AM, Brenner WJ, Herbst KL, Armony JK, et al. Low-dose
human chorionic gonadotropin maintains intratesticular testosterone in normal men with testosterone-induced gonadotropin suppression. J Clin Endocrinol Metab 2005; 90: 2595–602.

Hsieh TC, Pastuszak AW, Hwang K, Lipshultz LJ. Concomitant intramural human chorionic gonadotropin preserves spermatogenesis in men undergoing testosterone replacement therapy. J Urol 2013; 189: 647–50.

Turek PJ, Williams RH, Gilbaugh JH 3rd, Lipshultz LJ. The reversibility of anabolic steroid-induced azoospermia. J Urol 1995; 153: 1628–30.

Kaufman JM, Gin M, Deslypere JM, Thomas G, Vermeulen A. Influence of age on the responsiveness of the gonadotrophs to luteinizing hormone-releasing hormone in males. J Clin Endocrinol Metab 1991; 72: 1255–60.

Liu PY, Wishart SM, Handelsman DJ. A double-blind, placebo-controlled, randomized clinical trial of recombinant human chorionic gonadotropin on muscle strength and physical function and activity in older men with partial age-related androgen deficiency. J Clin Endocrinol Metab 2002; 87: 3125–35.

Glaser AF, Irvine DS, Wickings EJ, Hillier SG, Baird DT. A comparison of the effects on follicle development between clomiphene citrate, its two separate isomers and spontaneous cycles. Hum Reprod 1989; 4: 252–6.

Cargile CM, Ross GT, Bardin CW. Clomiphene and gonadotrophin in men. Lancet 1968; 2: 1298.

Santen RJ, Leonard JM, Sherins RJ, Gandy HM, Paulsen CA. Short- and long-term effects of clomiphene citrate on the pituitary-testicular axis. J Clin Endocrinol Metab 1971; 33: 970–9.

Winters SJ, Janick JJ, Loriaux DL, Sherins RJ. Studies on the role of sex steroids in the feedback control of gonadotropin concentrations in men. II. Use of the estrogen antagonist, clomiphene citrate. J Clin Endocrinol Metab 1979; 48: 222–7.

Tenover JS, Bremner WJ. The effects of normal aging on the response of the pituitary-gonadal axis to chronic clomiphene administration in men. J Androl 1991; 12: 258–63.

Lim VS, Fang VS. Restoration of plasma testosterone levels in uremic men with clomiphene citrate. J Clin Endocrinol Metab 1976; 43: 1370–7.

Guay AT, Bansal S, Hodge MB. Possible hypothalamic impotence. Male counterpart to hypothalamic amenorrhea? Urology 1991; 38: 317–22.

Guay AT, Bansal S, Heatley GJ. Effect of raising endogenous testosterone levels to spontaneous cycles. BJU Int 2004; 89: 1174–80.

Ramsamy R, Scovell JM, Kovac JR, Lipshultz LJ. Testosterone supplementation versus clomiphene citrate for hypogonadism: an age matched comparison of satisfaction and efficacy. J Urol 2014; 192: 875–9.

Mikkelsen TJ, Kroboth PD, Cameron WJ, Dittter LW, Chungi V, et al. Single-dose pharmacokinetics of clomiphene citrate in normal volunteers. Fertil Steril 1986; 46: 392–6.

Ghobadi C, Mirhosseini N, Shiran MR, Moghadamnia A, Lennard MS, et al. Single-dose pharmacokinetic study of clomiphene citrate isomers in anovular patients with polycystic ovary disease. J Clin Pharmacol 2009; 49: 147–54.

Wielhe RD, Podolski JS. Androxal (enclomiphene citrate) acts centrally on the hypothalamic-pituitary axis to increase LH, FSH, and testosterone in men with adult idiopathic hypogonadotropic hypogonadism. J Urol 2008; 179: 426.

Kaminetsky J, Werner M, Fontenot G, Wiehle RD. Oral enclomiphene citrate stimulates the endogenous production of testosterone and sperm counts in men with low testosterone: comparison with testosterone gel. J Sex Med 2013; 10: 1628–35.

Hill S, Arutchelvam V, Quinton R. Enclomiphene, an estrogen receptor antagonist for the treatment of testosterone deficiency in men. Drugs 2009; 12: 109–19.

Simpson ER, Mahendroo MS, Means GD, Kilgore MW, Hirshelwood MM, et al. Aromatase cytochrome P450, the enzyme responsible for estrogen biosynthesis. Endocr Rev 1994; 15: 342–55.

Morishima A, Grumbach MM, Simpson ER, Fisher C, Qin K. Aromatase deficiency in male and female siblings caused by a novel mutation and the physiological role of estrogens. J Clin Endocrinol Metab 1995; 80: 3689–98.

de Ronde W. Therapeutic uses of aromatase inhibitors in men. Curr Opin Endocrinol Diabetes Obes 2007; 14: 235–40.

AstraZeneca. Arimidex Package Insert. 2013. Available from: http://www1.astrazeneca-us.com/pi/rimonix.pdf. Last access Dec 15 2014

Yuan J, Wang PQ, Ge SR, An FR, Shi AG, et al. Pharmacokinetics of aromatase in Chinese male volunteers. Acta Pharmacol Sin 2001; 22: 573–6.

Smith EP, Boyd J, Frank GR, Takahashi H, Cohen RM, et al. Estrogen resistance caused by a mutation in the estrogen-receptor gene in a man. N Engl J Med 1994; 331: 1056–61.

Burnett-Bowie SA, McKay EA, Lee H, Leder BZ. Effects of aromatase inhibition on bone mineral density and bone turnover in older men with low testosterone levels. J Clin Endocrinol Metab 2009; 94: 4785–92.

Eastell R, Adams JE, Coleman RE, Howell A, Hannon RA, et al. Effect of aromatase on bone mineral density: 5-year results from the aromatase, tamoxifen, alone or in combination trial 1B233230. J Clin Oncol 2008, 26: 1051–7.

Ahokoski O, Irjala K, Huupponen R, Halonen K, Salminen E, et al. Hormonal effects of MPV22134d, a new selective aromatase inhibitor, in healthy male subjects. A phase I study. Br J Clin Pharmacol 1998; 45: 141–6.

Loves S, de Jong J, van Sorge A, Teltzing D, Tack CJ, et al. Somatic and psychological effects of low-dose aromatase inhibition in men with obesity-related hypogonadotropic hypogonadotropism. Eur J Endocrinol 2013; 169: 705–14.

de Ronde W, de Jong FH. Aromatase inhibitors in men: effects and therapeutic options. Reprod Biol Endocrinol 2011; 9: 93.

de Ronde W. Testosterone gel for the treatment of male hypogonadism. Expert Opin Biol Ther 2009; 9: 249–53.

Jarow JP, Chen H, Rosner TW, Trentacoste S, Zirkin BR. Assessment of the responsiveness of the gonadotrophs to luteinizing hormone-releasing hormone. J Androl 2001; 22: 640–5.

Clark RV, Sherins RJ. Treatment of men with idiopathic oligozoospermic infertility using the aromatase inhibitor, testolactone. Results of a double-blind, randomized, placebo-controlled trial with crossover. J Androl 1989; 10: 240–7.

Veldhuis JD, Infranesh A. Short-term aromatase-enzyme blockade unmasks impaired feedback adaptations in luteinizing hormone and testosterone secretion in older men. J Clin Endocrinol Metab 2005; 90: 211–8.

Leder BZ, Rohrer JL, Rubin SD, Gaillio J, Longcope C. Effects of aromatase inhibition in elderly men with low or borderline-low serum testosterone levels. J Clin Endocrinol Metab 2004; 89: 1174–80.